Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza Vaccination

Conditions

Influenza Vaccination

Trial Timeline

Sep 29, 2022 → Feb 6, 2024

About Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine

Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine is a phase 3 stage product being developed by Sanofi for Influenza Vaccination. The current trial status is completed. This product is registered under clinical trial identifier NCT05479370. Target conditions include Influenza Vaccination.

What happened to similar drugs?

20 of 20 similar drugs in Influenza Vaccination were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05479370Phase 3Completed

Competing Products

20 competing products in Influenza Vaccination

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1018 for H5N8ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0